Soy isoflavones group (n = 44) | Placebo group (n = 44) | P b | P c | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Baseline | End of trial | Change | P a | Baseline | End of trial | Change | P a | |||
Characteristics of migraine attack | ||||||||||
Attacks frequency ( per month) | 7.65 ± 2.44 | 5.29 ± 1.95 | -2.36 ± 1.20 | < 0.001 | 7.06 ± 1.43 | 6.63 ± 1.90 | -0.43 ± 1.35 | 0.040 | 0.002 | < 0.001 |
Severity | 7.06 ± 1.63 | 6.13 ± 1.78 | -0.93 ± 1.95 | 0.003 | 6.65 ± 1.62 | 6.34 ± 1.66 | -0.31 ± 1.61 | 0.197 | 0.580 | 0.189 |
Attacks duration (hr) 1 | 10.38. ± 4.35 | 7.88 ± 3.50 | -2.50 ± 1.74 | < 0.001 | 10.61 ± 2.08 | 10.63 ± 2.80 | -0.02 ± 2.15 | 0.944 | < 0.001 | < 0.001 |
Clinical indices of migraine | ||||||||||
MI (frequency * severity) | 55.77 ± 26.10 | 32.02 ± 14.65 | -23.75 ± 18.19 | < 0.001 | 47.29 ± 15.94 | 42.75 ± 17.87 | -4.54 ± 12.89 | 0.024 | 0.003 | < 0.001 |
HDR (frequency * duration) | 80.04 ± 41.23 | 42.84 ± 26.29 | -37.20 ± 22.38 | < 0.001 | 74.79 ± 24.23 | 70.13 ± 24.11 | -4.65 ± 20.22 | 0.134 | < 0.001 | < 0.001 |
MHIS (frequency * duration * severity) | 19.18 ± 11.24 | 8.72 ± 5.91 | -10.46 ± 7.43 | < 0.001 | 16.59 ± 6.99 | 15.12 ± 6.90 | -1.47 ± 5.25 | 0.069 | < 0.001 | < 0.001 |